Search

Your search keyword '"Mells, George"' showing total 297 results

Search Constraints

Start Over You searched for: Author "Mells, George" Remove constraint Author: "Mells, George"
297 results on '"Mells, George"'

Search Results

1. COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.

2. Latent class mixed modelling for phenotypic stratification of primary biliary cholangitis patients on first line treatment

3. Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery

4. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

5. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis

7. Anti–Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct–Ligated Mice

8. THU-125 Key questions that patients with primary biliary cholangitis should ask their physician -Delphi method-

9. THU-101 Non-invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis based on the cholestasis degree

10. Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

12. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

14. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score

16. Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery

17. Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform

21. P32 Statistical colocalization identifies twenty-four novel risk loci associated with disease risk of primary biliary cholangitis

23. Identification of potential targets amenable to novel therapeutics to treat symptoms in primary biliary cholangitis

24. Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis

25. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

27. Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells

28. Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581]

29. Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells

32. Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?

33. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

34. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

35. O07 Results of the first national audit of PBC management reveal significant variation in care delivery across the UK

36. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581]

37. Critical shortfalls in the management of PBC: results of the first nationwide, population-based study of care delivery across the U.K.

38. UK-PBC National Audit: a collaborative success in identifying critical shortfalls

39. The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System

40. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study

42. Su1357: PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER EVENT-FREE SURVIVAL OUTCOMES THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS

44. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

45. Neurosteroid activation of gaba-a receptors : a potential treatment target for symptoms in primary biliary cholangitis?

46. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls

47. The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis

48. rs9459874 and rs1012656 in CCR6/FGFR1OP confer susceptibility to primary biliary cholangitis

49. OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience

50. The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis

Catalog

Books, media, physical & digital resources